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The interventional cardiologist must be able to recognize and manage potential vascular
complications. Iliofemoral complications are the most frequent vascular complications in transfemoral
transcatheter aortic valve implantation. Small vessel dimensions, moderate or severe calciﬁcation, and
center experience are the major predictors. The traditional treatment for injured arteries has been
surgical reconstruction, but endovascular techniques may allow for less invasive but effective
management of arterial injuries. Dissection may be treated with prolonged balloon inﬂation or
deployment of a self-expanding or balloon-expandable stent or a surgical graft. Iliofemoral rupture is
a serious complication that may lead to retroperitoneal bleeding that can be unrecognized. Rapid
insertion of a dilator or sheath or an occlusive balloon is used to achieve hemostasis. Prolonged
balloon inﬂation or implantation of a covered stent or surgical repair should then be considered.
Treatment options for failed percutaneous closure include prolonged manual compression, balloon
angioplasty, stent implantation, and surgery. Aortic complications are rare, but serious complications
are associated with a high mortality rate, even if emergent surgery is performed. There are speciﬁc
vascular complications associated with alternative access routes such as transapical and transaxillary
and direct aortic access. (J Am Coll Cardiol Intv 2013;6:767–76) ª 2013 by the American College of
Cardiology FoundationVascular complications are a major cause of
morbidity and mortality in transcatheter aortic
valve implantation (TAVI) due to the large-
bore catheters required. In this paper, we review
the frequency and causes of and treatment
options for different vascular complications.
Deﬁnitions of Vascular Complications
Most studies have used nonstandardized deﬁ-
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768Clinical Relevance of Vascular Complications
Frequency. The frequency of vascular complications in
transfemoral TAVI is summarized in Table 1. Reported rates
of (major) vascular complications range from 1.9% to 17.3%
(7–20).
Impact on mortality. Vascular complications have been
associated with morbidity, reduced quality of life, and
increased costs. Several studies have shown that mortality is
higher in patients with vascular complications than in those
without (odds ratios ranging from 2.4 to 8.5) (9,20–23).
Impact on length of hospital stay. Hospital stay was signif-
icantly longer in patients with major complications (16 days)
than in those with minor (11 days) or no vascular compli-
cations (6 days) (24). Another study yielded similar ﬁndings
with hospital stays of 17 and 10 days in patients with and
without major vascular complications, respectively (20).
Vascular Complications of the Iliofemoral Arteries
Iliofemoral complications are the most common vascular
complications in transfemoral TAVI. Studies have identiﬁed
small vessel dimensions (minimal artery diameter smallerAbbreviations
and Acronyms
TAVI = transcatheter aortic
valve implantation
VARC = Valve Academic
Research Consortiumthan the external sheath diameter
or sheath-to-femoral artery ratio
>1.05), moderate or severe iliofe-
moral calciﬁcation, and center
experience as major predictors of
iliofemoral vascular complications
(Table 2) (19,20,24). In our expe-
rience, the combination of an ilio-femoral artery diameter smaller than the external sheath size
and the concomitant presence of moderate or severe calciﬁca-
tion is associated with the highest vascular complication rate.
In such patients, alternative access routes should be preferred.
Iliofemoral tortuosity was not found to predict vascular
complications (20,24). Usually, the artery straightens out as
soon as the stiff wire is advanced through the tortuous part
of the artery (Fig. 1).
The traditional treatment for injured arteries has been
surgical reconstruction (25). Although the success rate for
surgical treatment is high, there are often considerable
morbidity and mortality (26). Surgical access, in combina-
tion with hematoma and various comorbidities, often
predisposes to poor wound healing and infection in these
often elderly and comorbid patients (27,28). Endovascular
techniques may allow for less invasive yet effective
management of arterial injuries.
Iliofemoral dissection. Dissection of the iliofemoral artery
requiring percutaneous or surgical intervention has been
reported in 2.0% to 7.4% of patients undergoing trans-
femoral TAVI with a surgical cutdown and in 1.6% to
21.4% of patients undergoing percutaneous closure
(20,23,24,29–36).Whether a dissection requires treatment depends on
the extent and hemodynamic relevance. Usually, prolonged
inﬂation of a balloon with appropriate diameter results in
successful apposition of the intima and underlying media.
However, more extensive dissection may warrant self-
expanding or balloon-expandable stent deployment or a
surgical graft (23,28,29,31–34,36).
Several cases of stent thrombosis have been reported after
treatment of dissections with stents. Therefore, temporary
treatment with heparin (in addition to aspirin and clopi-
dogrel) should be considered in such patients. The mortality
of iliofemoral dissection is low.
Iliofemoral rupture. Rupture can occur if the delivery sheath
is inserted in a small, calciﬁed artery. Rupture of the ilio-
femoral artery has been reported in both patients undergoing
transfemoral TAVI with a surgical cutdown (4.0% to 9.3%)
and in patients undergoing percutaneous closure (0.7% to
7.1%) (20,23,24,29–38). Most of the patients reported in
literature were treated with surgery, some with a covered
stent. Although a detailed outcome was not reported in all,
at least 6 of 30 (20%) with ruptured iliac and/or femoral
arteries died. Retroperitoneal bleeding after rupture can be
unrecognized, and, therefore, in cases with borderline ilio-
femoral anatomy, angiography should be performed from
the ipsi- or contralateral side during or after retrieval of the
large sheath.
When rupture or bleeding is detected, options include
rapid insertion of a dilator or sheath or, alternatively, an
occlusive balloon can be inserted (from the ipsilateral or
contralateral femoral) to achieve hemostasis. In case of a
smaller perforation, crossover balloon inﬂation for up to 5 to
10 min may be enough to stop the bleeding (Fig. 2). If there
is ongoing bleeding, implantation of a covered stent (Fig. 3)
or surgical repair should be considered. If major vascular
injury occurs, endovascular occlusion with an occlusion
balloon (e.g., Reliant Stent Graft Balloon Catheter, Med-
tronic, Minneapolis, Minnesota; Berenstein Occlusion
Balloon Catheter, Boston Scientiﬁc, Natick, Massachusetts;
or Coda Occlusion Balloon Catheter, Cook Medical Inc.,
Bloomington, Indiana) may be life saving (Figs. 4 and 5).
These balloons are highly compliant and elongate without
undue radial force once they reach the vessel diameter. The
degree of inﬂation is monitored by ﬂuoroscopy. After acute
control of the hemorrhage is achieved, deﬁnitive therapy
with surgical repair or implantation of a covered stent is
performed (39).
Access site infection. The risk of access site infection after
suture-mediated closure has previously been described (40).
In TAVI, access site infections were reported in 1.6% to
6.3% of transfemoral cases (11,15,20,30,36,38,41). In the
PARTNER 1A (Placement of Aortic Transcatheter Valves)
study, 7 of 348 of the patients (2.0%) had a skin infection at
the puncture site. This rate was similar to the 2.0% of
patients presenting with a sternal wound infection after
Table 1. Vascular Access and Complication Rate in Larger Series (100 Patients) of Predominantly Transfemoral Transcatheter Aortic Valve Implantation
First Author (Year) N Sheath Size, F Technique
Vascular Complication
Rate, %*
VARC
Deﬁnition
Piazza et al. (2008) 646 18–21 Percutaneous, ProStary 1.9 No
Bleiziffer et al. (2009) 137 18–24 Mostly percutaneous, ProStary 11.7 No
Webb et al. (2009) 113 22–24 Mostly surgical cutdown 8.0 No
Leon et al. (2010) 179 22–24 Surgical cutdown 16.2 Yes
Tamburino et al. (2011) 679 18–24 Mostly percutaneous, ProStary 2.0 No
Smith et al. (2011) 348 22–24 Surgical cutdown 11.0 Yes
Gurvitch et al. (2011) 310 18–24 Mostly percutaneous, ProGlidey 11.7 Yes
Lange et al. (2011) 412 18–24 Mostly percutaneous, ProStary 10.2 No
Hayashida et al. (2011) 130 18–24 Mostly percutaneous, ProStary 17.3 Yes
Stähli et al. (2011) 130 18–24 Mostly percutaneous 11.5 Yes
Nuis et al. (2011) 165 18 Mostly percutaneous 15.0 Yes
Moat et al. (2011) 599 22–24 Not reported 8.4 No
Toggweiler et al. (2012) 137 18–24 Percutaneous, ProGlidey 5.6 Yes
Gilard et al. (2012) 2361 18–24 Not reported 5.5 Yes
*Major vascular complication rate reported in series that used VARC deﬁnitions. yProStar and ProGlide closure systems, Abbott Vascular, Abbott Park, Illinois.
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769surgical aortic valve replacement (11). Skin infections appear
to be more common in patients undergoing a cutdown to
expose the femoral artery. Of 19 patients with infection
reported in the literature, 16 occurred in patients undergoing
a planned surgical cutdown, and only 3 in patients under-
going percutaneous closure. In general, superﬁcial wound
infections should respond to local and/or systemic therapy.
However, a deep periarterial infection may result in signif-
icant morbidity. Death occurred in 2 of 19 patients (10.5%),
due to sepsis in 1 patient (20,41).
Stenosis/thrombosis/occlusion. Percutaneous closure with
either ProGlide Suture-Mediated Closure System or ProS-
tar XL Percutaneous Vascular Surgical System (Abbott
Vascular, Abbott Park, Illinois) is usually associated with
mild stenosis of the common femoral artery that is clinically
asymptomatic (24). Post-dilation of the closure site can be
performed in case of a more severe stenosis (32,35). Stenting
should rarely be necessary.
Thrombosis can occur after hemostasis, for example, after
crossover balloon-inﬂation. These patients can be treated
with surgical revascularization or balloon angioplasty (32),
but there is a risk of distal thromboembolization resulting in
reduced perfusion of the limb (33).
Artery avulsion. Adhesion of the sheath to the iliofemoral
artery is an unusual complication (32,42). In patients with
borderline iliofemoral arteries, the sheath can adhere directlyTable 2. Predictors of Vascular Complications
First Author (Year) N
Lange et al. (2011) 412 Center experience, plan
Hayashida et al. (2011) 130 Sheath-to-femoral arter
Toggweiler et al. (2012) 137 Sheath diameter greate
Généreux et al. (2011) 419 Female sexto the endothelium. The operator feels resistance during
sheath withdrawal and sudden hemorrhage may occur. The
risk of avulsion is reduced with smaller sheaths, periodic
sheath rotation (not advisable with the expandable sheath),
and early sheath removal (42). If avulsion is suspected, an
occlusion balloon should be placed, and the patient should
be prepared for possible surgical repair.
Pseudoaneurysms. Pseudoaneurysm formation can occur
when the arterial puncture site seals incompletely, resulting
in contained bleeding into the soft tissue within a pseudo-
capsule (43). The diagnosis should be suspected in a patient
with a painful, pulsatile groin mass. A murmur may be heard
on auscultation. Risk factors for pseudoaneurysms are
increasing sheath size, advanced age, cannulation of an
artery other than the common femoral artery, calciﬁcation,
increased body mass index, female sex, current anticoa-
gulation, combined arterial and venous puncture, and failure
to provide appropriate compression (44). Several studies
have reported spontaneous closure of pseudoaneurysms in
>50% of cases. Therefore, it appears reasonable to observe
a pseudoaneurysm if the size is <3.0 to 3.5 cm, there is no
associated pain, and no need for oral anticoagulation (45–47).
Treatment options are ultrasound-guided compression and
ultrasound-guided thrombin injection. In studies investi-
gating both, success rates for ultrasound-guided thrombin
injection were consistently higher (93% to 100%) than afterPredictors
ned surgical cutdown reduced vascular complication rate
y ratio, femoral calciﬁcation, center experience
r than minimal artery diameter, moderate/severe femoral calciﬁcation, learning curve
Figure 1. Transcatheter Aortic Valve Implantation in Patients With Iliofemoral Tortuosity
A patient with tortuosity of his external iliac artery (A, arrow) that straightened out after it was crossedwith thewire and the sheath. However, the sheath kinked (B, arrow),
but the procedure was successfully carried out after the sheath was replaced. Contralateral angiography showed minimal stenosis after closure with ProGlide system
(Abbott Vascular, Abbott Park, Illinois) (C). Extensive tortuosity of the external iliac artery (D) that straightened out with an Amplatz Extra Stiff Wire (Cook Medical Inc.,
Bloomington, Indiana) and an 18-F Edwards sheath (Edwards Lifesciences, Irvine, California) (E). Crossover angiography conﬁrmed a good result after closure (F).
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770ultrasound-guided compression (0 to 87%) (40,48–54).
Ultrasound-guided thrombin injection is considered to be
very safe, with complications such as infection, thrombosis,
and distal embolization occurring in <1% of cases (44).
Patients in whomminimally invasive techniques failed should
undergo surgical repair.
Failed percutaneous closure. Failed closure with a ProStar
or Perclose ProGlide (Abbott Vascular) requiring interven-
tion or surgery or leading to relevant bleeding has been
described in 4.4% to 8.7% of cases (18- to 24-F sheaths)
(20,32,35–37). Of 30 cases of failed percutaneous closure
reported in the literature, 7 (23%) were treated with surgery,
4 (13%) with prolonged manual compression only, 5 (17%)
with stent implantation, 3 (10%) with balloon angioplasty,
and 1 (3%) with aortic balloon occlusion and manual
compression.Access site bleeding. In patients undergoing percutaneous
coronary intervention, bleeding has been shown to be
associated with prolonged hospital stay, increased need for
blood transfusion, and mortality (55–57). Furthermore,
blood transfusion has been directly linked with excess
mortality (58). The possible mechanisms include pro-
thrombotic effects, impaired oxygen delivery of transfused
erythrocytes, microvascular obstruction, and transfusion
related immunomodulation (59). In transfemoral TAVI,
access site bleeding was reported in 2.2% to 12.5%
(20,24,29,37,38,41). A large hematoma can form very
quickly despite manual compression and warrants immediate
action. A catheter should be advanced from the contralateral
side to achieve control of the artery. A smaller injury of
the femoral artery can usually be managed with balloon
occlusion. If a larger injury occurs, a stent-graft should be
Figure 2. Treatment of Femoral Artery Injury With a Balloon Catheter
This patient presented with stenosis and ongoing bleeding of the common femoral artery after closure with the ProGlide system (Abbott Vascular, Abbott Park, Illinois)
(A). An 8  40-mm balloon was inﬂated (B), resulting in hemostasis and moderate, asymptomatic residual stenosis (C). This complication was managed without
protamine reversal.
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771implanted (60). Self-expanding nitinol stents are preferred
over balloon-expandable stents because they are more
resistant to external compression and bending stress (61).
Aortic Complications
Aortic complications such as aortic dissection and perforation
have been reported in 0 to 1.9% of patients undergoing
transfemoral TAVI (17,20,22,23,30,34,35,62). These serious
complications are associated with a very high mortality rate.
Aortic aneurysms. Aneurysms of the iliac arteries or the
abdominal aorta are frequently present in patients under-
going TAVI (Fig. 6). Usually, these aneurysms can beFigure 3. Treatment of Femoral Artery Injury With a Covered Stent
(A) This patient presented with acute hemorrhage of the femoral artery. Bleeding was
self-expanding stent-graft (Bard Canada Inc., Oakville, Ontario, Canada) was implantepassed with the delivery sheath without any problems. A
delayed lethal rupture of the descending aorta has been
reported in a patient with a previously stent-treated abdo-
minal aneurysm 4 h after transfemoral TAVI (19). In
a minority of patients, iliofemoral access is suitable for
transfemoral TAVI, but there is relevant kinking of the
aorta. More than slight kinking of the thoracic or abdominal
aorta may lead to difﬁculties when trying to position the
valve for implantation (19). In this case, an alternative access
route should be preferred.
Aortic rupture. Acute or delayed aortic annular rupture is
a rare but serious complication with a very poor prognosis,
even if emergent surgery is performed (31,33,63,64).controlled with balloon tamponade and then, a Fluency Plus 9 60-mm covered
d with a good result (B,C).
Figure 4. Examples of Occlusion Balloon Catheters
Berenstein occlusion balloon catheter (Boston Scientiﬁc, Natick, Massachusetts) (A) and Coda Occlusion Balloon Catheter (Cook Medical Inc., Bloomington, Indiana) (B).
(C) Inﬂated occlusion balloon in the left femoral artery. Note that the balloon assumes the shape of the artery and expands longitudinally once the vessel walls are
reached.
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772Rupture of the descending aorta or the annulus has been
reported in 0 to 2.0% of patients undergoing TAVI
(11,19,20,24,30,31,33,35). Annular rupture may occur after
balloon valvuloplasty or after valve implantation (more
frequently with balloon-expandable valves) and lead to acuteFigure 5. Occlusion of the Aorta to Treat a Femoral Bleeding
This patient had a perforated right common femoral artery (A, arrow). An occlusion b
was implanted to treat the perforation (C, arrow).rupture, cardiac tamponade, or death. Two cases of delayed
aortic annulus rupture 24 h and 27 h after implantation of
the Medtronic CoreValve (Medtronic, Minneapolis, Min-
nesota) have been described (19). Meticulous measurement
of the annulus with multi-slice computed tomography oralloon was inﬂated in the lower abdominal aorta (B, arrow), and a covered stent
Figure 6. Transcatheter Aortic Valve Implantation in Patients With Iliofemoral or Aortic Aneurysms
Patients with iliac (A,B), abdominal (C,D), or both iliac and abdominal (E,F) aneurysms are not infrequent. Careful passage of a guidewire followed by over-the-wire
passage of catheters can generally be accomplished with low risk.
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774biplane transesophageal echocardiography may reduce the
risk of extreme oversizing (65–67). The risk of perforation
may be higher in patients with a very calciﬁed valve. On the
other hand, an undersized valve may lead to moderate/severe
paravalvular regurgitation or embolization of the valve (66).
Aortic dissection. Aortic dissection has been reported in 0 to
1.9% of transfemoral TAVI cases (11,20,22,24,35,62).
Traditionally, the treatment for most patients with injury of
the descending aorta has been surgical intervention with
graft interposition (68). More recently, endoluminal stent-
graft procedures have become increasingly popular and are
associated with lower mortality and paraplegia rates than
open repair (68).
Retroperitoneal hemorrhage. A retroperitoneal bleed can be
caused by injury of the aorta, the iliac or proximal common
femoral artery, or a small branch vessel such as the inferior
epigastric artery. Bleeding may occur after incomplete closure
if the sheath is removed from the proximal common femoral
artery or the external iliac artery. The diagnosis is often
delayed as symptoms are nonspeciﬁc (hemodynamic insta-
bility, groin/ﬂank/abdominal/back pain) (69). When a retro-
peritoneal hematoma is suspected, computed tomography or
angiography should be performed to conﬁrm the diagnosis.
After TAVI, retroperitoneal hemorrhage has been re-
ported in 0 to 2.2% of cases (17,24,30,33,36,37,41). TAVI
patients who often present with poor cardiac reserve and
severe comorbidities may be at increased risk of mortality in
the context of bleeding.
Most of the retroperitoneal hematomas do not require
intervention and can be managed with administration of
ﬂuids, normalization of coagulation factors, and blood
transfusion (69). If the patient becomes unstable or the
hemoglobin does not respond to blood transfusion, angiog-
raphy may be able to identify the source of bleeding.
Temporary balloon occlusion may be enough to achieve
hemostasis in cases of smaller injuries. A larger injury of the
iliac artery can be treated with a covered stent. Rupture of
a small branch such as the inferior epigastric artery may be
treated with a coil embolization, balloon tamponade, a
covered stent, or surgery. A high groin exposure or retroper-
itoneal incision is usually performed with direct suture repair
of the injury (37,41,43).
Vascular Complications Associated With
Alternative Access Routes
Vascular complications associated with transapical access.
The most frequent acute complications are bleeding from
the apical puncture site and myocardial tears requiring
further surgical repair (70,71). Apical scarring resulting from
a hematoma or myocardial sutures may result in local
hypokinesis. This may be a problem in patients with a low
pre-procedural ejection fraction but preserved apical
contraction (72). A puncture close to the left anteriordescending coronary artery may lead to tension resulting in
ﬂow obstruction (73). Long-term complications include
aneurysm formation, chronic pain caused by rib retraction,
pleural dissection, and intercostal nerve damage
(15,22,31,38,74–76).
Vascular complications associated with transaxillary access.
Manipulation of a large sheath inside the axillary and
subclavian artery can cause vascular injury. Thrombosis of
the subclavian artery has been reported after transaxillary
TAVI (33). Lange et al. (19) reported the outcomes of
28 patients; 1 patient had a subclavian artery injury during
CoreValve implantation, and the vessel was repaired by
interposition of a vascular prosthesis. One patient had
a asymptomatic subclavian artery dissection after CoreValve
implantation. Dissection of the left subclavian artery may be
a problem in patients with a patent left internal mammary
artery graft (77).
Vascular complications associated with transaortic access. In
elderly and frail patients, the aortic wall may be fragile, and
tearing of the aorta may occur when tightening the sutures.
Other speciﬁc complications of the direct aortic access
include deep wound infection or mediastinitis after partial
sternotomy. A right mini-thoracotomy may lead to injury of
a right internal mammary graft. Rare complications with
transaortic access include laceration of the right ventricle
after right mini-thoracotomy and pseudoaneurysm forma-
tion of an intercostal artery after mini-sternotomy
(72,73,78–82).
Summary
Although vascular complications will continue to occur, we
believe that with lower proﬁle sheaths, better screening
techniques, appropriate choice of access site, and operator
experience, lower complication rates will be achieved in future
clinical trials and clinical routine. Nevertheless, the inter-
ventional cardiologist must be able to recognize and manage
potential vascular complications. With increased experience,
most of the vascular complications associated with the
transfemoral approach may be managed percutaneously.
We believe that speciﬁc access site complication rates
should be reported rather than overall minor and major
vascular complications so that readers may know which
issues have improved and which remain a problem as TAVI
technology advances.
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